Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Turning Point Therapeutics Inc (TPTX)

Turning Point Therapeutics Inc (TPTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,806,125
  • Shares Outstanding, K 50,074
  • Annual Sales, $ 30,830 K
  • Annual Income, $ -236,550 K
  • 60-Month Beta -0.18
  • Price/Sales 122.61
  • Price/Cash Flow N/A
  • Price/Book 4.76
Trade TPTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -6.90
  • Most Recent Earnings $-2.48 on 08/08/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -2.06
  • Number of Estimates 6
  • High Estimate -1.57
  • Low Estimate -2.89
  • Prior Year -1.34
  • Growth Rate Est. (year over year) -53.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
74.57 +1.93%
on 07/21/22
76.01 unch
on 08/16/22
+1.36 (+1.82%)
since 07/15/22
3-Month
30.85 +146.39%
on 05/25/22
76.01 unch
on 08/16/22
+43.53 (+134.02%)
since 05/16/22
52-Week
23.77 +219.77%
on 03/15/22
82.20 -7.53%
on 09/02/21
+9.27 (+13.89%)
since 08/16/21

Most Recent Stories

More News
Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics

Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) (“Turning Point”) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements...

BMY : 40.45 (-2.06%)
TPTX : 76.01 (+0.69%)
Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates

Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of...

TPTX : 76.01 (+0.69%)
Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC

Completed pre-NDA meeting to discuss proposed patient follow-up in ROS1+ advanced NSCLC with FDA...

TPTX : 76.01 (+0.69%)
Bristol Myers Squibb Reports Second Quarter Financial Results for 2022

Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2022, which reflect continued in-line product growth, strong momentum across the new product portfolio and continued pipeline...

BMY : 40.45 (-2.06%)
TPTX : 76.01 (+0.69%)
IMTX : 12.02 (+0.17%)
Bristol Myers Squibb Announces Extension of Turning Point Tender Offer

Bristol Myers Squibb (NYSE:BMY) today has announced that Rhumba Merger Sub Inc. (“Offeror”), a wholly owned subsidiary of Bristol Myers Squibb, has extended the expiration date of its offer (the “Offer”)...

BMY : 40.45 (-2.06%)
TPTX : 76.01 (+0.69%)
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates TPTX, DRE, CVET, YMTX

/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

TPTX : 76.01 (+0.69%)
DRE : 48.20 (+0.48%)
CVET : 20.99 (+0.29%)
YMTX : 13.2300 (+8.62%)
TPTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Turning Point Therapeutics, Inc. Is Fair to Shareholders

Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Turning Point Therapeutics, Inc. (NASDAQ: TPTX) to Bristol Myers Squibb for $76.00 per share is fair to Turning Point...

TPTX : 76.01 (+0.69%)
TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Turning Point Therapeutics, Inc. (NasdaqGS:...

TPTX : 76.01 (+0.69%)
BMY : 40.45 (-2.06%)
SHAREHOLDER ALERT: Weiss Law Reminds MBII, VMW, TPTX, and HMTV Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

MBII : 0.7981 (-20.19%)
VMW : 142.48 (-4.96%)
TPTX : 76.01 (+0.69%)
HMTV : 7.15 (+1.56%)
Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies

HOUSTON and SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company...

TPTX : 76.01 (+0.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients. Their internally developed and wholly owned pipeline of next-generation...

See More

Key Turning Points

3rd Resistance Point 76.05
2nd Resistance Point 76.03
1st Resistance Point 76.02
Last Price 76.01
1st Support Level 75.99
2nd Support Level 75.97
3rd Support Level 75.96

See More

52-Week High 82.20
Last Price 76.01
Fibonacci 61.8% 59.88
Fibonacci 50% 52.99
Fibonacci 38.2% 46.09
52-Week Low 23.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar